Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1

Six recombinant human Fab fragments that were derived from the same human immunodeficiency virus type 1 (HIV-1)-infected individual and are directed against the CD4 binding site (CD4bs) of the gp120 envelope glycoprotein were studied. A range of neutralizing activity against the HIV-1 (HXBc2) isolate was observed, with Fab b12 exhibiting the greatest potency among the Fabs tested. The neutralizing potency of Fab b12 was better than that of monoclonal whole antibodies directed against the third variable (V3) region of gp120. To explore the basis for the efficient neutralizing activity of b12, the recognition of a panel of HIV-1 gp120 mutants by the six Fabs was studied. The patterns of sensitivity to particular gp120 amino acid changes were similar for all six Fabs to those seen for anti-CD4bs monoclonal antibodies derived from HIV-1-infected individuals by conventional means. In addition, recognition by Fab b12 demonstrated an atypical sensitivity to changes in the V1 and V2 variable regions. Next, the binding of the Fabs to monomeric gp120 and to the envelope glycoprotein complex was examined. Neither the binding properties of the b12 Fab to monomeric gp120 nor the ability of the Fab to compete with soluble CD4 for monomeric gp120 binding appeared to account for the greater neutralizing potency. However, both quantitative and qualitative differences between the binding of b12 and that of less potent Fabs to the cell surface envelope glycoprotein complex were observed. Relative to less potently neutralizing Fabs, Fab b12 exhibited a higher affinity for a subpopulation of cell surface envelope glycoproteins, the conformation of which was best approximated by the mature gp120 glycoprotein. Apparently, subtle differences in the gp120 epitope recognized allow some members of the group of anti-CD4bs antibodies to bind to the functionally relevant envelope glycoprotein complex and to neutralize virus more efficiently.

[1]  D R Burton,et al.  In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Morrow,et al.  Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. , 1992, Journal of immunology.

[3]  M. Kieny,et al.  Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. , 1992, Science.

[4]  C. Barbas,et al.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Sullivan,et al.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.

[6]  D R Burton,et al.  Human antibodies to HIV-1 by recombinant DNA methods. , 1993, Chemical immunology.

[7]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[8]  M Ohlin,et al.  Real Time Analysis of Antibody‐Antigen Reaction Kinetics , 1992, Scandinavian journal of immunology.

[9]  J. Moore,et al.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.

[10]  Dennis R. Burton,et al.  Antibodies from libraries , 1992, Nature.

[11]  T. White,et al.  The origin of HIV-1 isolate HTLV-IIIB , 1993, Nature.

[12]  S. Zolla-Pazner,et al.  Epitopes of HIV-1 glycoproteins recognized by the human immune system. , 1993, Chemical immunology.

[13]  D R Burton,et al.  Human antibodies from combinatorial libraries. , 1994, Advances in immunology.

[14]  G R Pilkington,et al.  Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. , 1993, Journal of molecular biology.

[15]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[16]  G K Lewis,et al.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.

[17]  R. Redfield,et al.  Real-time biospecific interaction analysis of antibody reactivity to peptides from the envelope glycoprotein, gp160, of HIV-1. , 1992, Journal of immunological methods.

[18]  W. Schleif,et al.  Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody , 1992, Nature.

[19]  J. Cohen,et al.  Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120. , 1989, Journal of immunology.

[20]  J. Sodroski,et al.  Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.

[21]  K. Steimer,et al.  HIV-1 neutralization directed to epitopes other than linear V3 determinants. , 1991, AIDS.

[22]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[23]  L. Lasky,et al.  Model for intracellular folding of the human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[24]  C. Milstein,et al.  Original and artificial antibodies , 1992, Nature.

[25]  R. Cheynier,et al.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. , 1991, Science.

[26]  D. Burton,et al.  Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. , 1993, Human antibodies and hybridomas.

[27]  M. Champe,et al.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.

[28]  D R Burton,et al.  Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. , 1989, Science.

[29]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[30]  D R Burton,et al.  A binary plasmid system for shuffling combinatorial antibody libraries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Kieny,et al.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  N. Haigwood,et al.  Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals , 1993, Journal of virology.

[33]  J. Goudsmit,et al.  Neutralization of HIV‐1: a paradox of humoral proportions , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  C. Barbas,et al.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Matsushita,et al.  Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees , 1990, Journal of virology.